Enzymatic method for preparation of UDP-GlcNAc

US11767546B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11767546-B2
Application numberUS-202017755653-A
CountryUS
Kind codeB2
Filing dateSep 30, 2020
Priority dateNov 5, 2019
Publication dateSep 26, 2023
Grant dateSep 26, 2023

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to an enzyme-catalyzed process for producing UDP-N-acetyl-α- D -glucosamine (UDP-GlcNAc) from low-cost substrates uridine monophosphate and N-acetyl- D glucosamine in a single reaction mixture with immobilized or preferably co-immobilized enzymes. Uridine may be used as starting material instead of uridine monophosphate as well. Further, the process may be adapted to produce GlcNAcylated molecules and biomolecules including saccharides, particularly human milk oligosaccharides (HMO), proteins, peptides, glycoproteins, particularly antibodies, or glycopeptides, and bioconjugates, particularly carbohydrate conjugate vaccines and antibody-drug conjugates.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method for producing uridine 5′-diphospho-N-acetyl-α-D-glucosamine comprising: providing a solution comprising (i) uridine monophosphate and N-acetyl-D-glucosamine represented by the following formulae (ii) polyphosphate, and adenosine triphosphate; and providing a set of enzymes comprising a glucose-1-phosphate uridylyltransferase, an N-acetylhexosamine kinase, a polyphosphate kinase, and a uridine monophosphate kinase; A) producing uridine 5′-diphospho-N-acetyl-α-D-glucosamine from uridine monophosphate and N-acetylglucosamine in the presence of the set of enzymes, polyphosphate, and adenosine triphosphate, wherein the set of enzymes is covalently or adsorptively immobilized on a reusable, mechanically stable solid support. 2. The method according to claim 1 , wherein the set of enzymes is co-immobilized on the solid support. 3. The method according to claim 1 , wherein the set of enzymes is covalently immobilized on a reusable, mechanically stable solid support. 4. The method according to claim 1 , wherein the solid support is composed of beads or resins comprising a polymer with epoxide functional groups, with amino epoxide functional groups, with ethylenediamine functional groups, with amino C2 functional groups, with amino C6 functional groups, with anionic/amino C6 spacer functional groups. 5. The method according to claim 1 , wherein the solid support is a polymer functionalized with epoxy groups. 6. The method according to claim 1 , wherein the set of enzymes further comprises a pyrophosphatase. 7. The method according to claim 1 , wherein the set of enzymes is directly co-immobilized on a solid support from fermentation broth, crude cell lysate, purified cell lysate or cell homogenate. 8. The method according to claim 1 , wherein the set of enzymes further comprises a one-domain polyphosphate kinase 2 and/or wherein the set of enzymes further comprises a two-domain polyphosphate kinase 2. 9. The method according to claim 1 , wherein the concentration of adenosine triphosphate in the solution provided in A) is in the range of 0.001 moles to 0.9 moles per mole N-acetyl-D-glucosamine. 10. The method according to claim 1 , wherein the concentration of uridine monophosphate and N-acetyl-D-glucosamine in the solution provided in A) is in the range of 0.2 mM to 15,000 mM. 11. The method according to claim 1 , wherein the uridine 5′-diphospho-N-acetyl-α-D-glucosamine is produced in a single reaction mixture. 12. The method according to claim 1 , wherein the uridine monophosphate in A) is obtained from (i) uridine, adenosine triphosphate and a uridine kinase; or (ii) uracil, 5-phospho-α-D-ribose 1-diphosphate and an uracil phosphoribosyltransferase; or (iii) from orotic acid, 5-phospho-α-D-ribose 1-diphosphate, an orotate phosphoribosyltransferase and a UMP transferase. 13. The method according to claim 1 , further comprising producing a GlcNAcylated saccharide, a GlcNAcylated glycopeptide, a GlcNAcylated glycoprotein, a GlcNAcylated protein, a GlcNAcylated peptide, a GlcNAcylated bioconjugate or a GlcNAcylated small molecule from uridine 5′-diphospho-N-acetylglucosamine and a saccharide, glycopeptide, glycoprotein, protein, peptide, bioconjugate or small molecule by forming an O-glycosidic bond between uridine 5′-diphosphoN-acetylglucosamine and an available hydroxyl group of the saccharide, glycopeptide, glycoprotein, protein, peptide, bioconjugate or small molecule in the presence of an N-acetylglucosaminyltransferase. 14. The method according to claim 13 , wherein the saccharide, glycopeptide, glycoprotein, protein, peptide, bioconjugate or small molecule is an antibody or a monoclonal antibody; or a human milk oligosaccharide or a bioconjugate. 15. The method according to claim 13 , further comprising recycling of uridine diphosphate formed from the producing a GlcNAcylated saccharide, a GlcNAcylated glycopeptide, a GlcNAcylated glycoprotein, a GlcNAcylated protein, a GlcNAcylated peptide, a GlcNAcylated bioconjugate or a GlcNAcylated small molecule from uridine 5′-diphospho-N-acetylglucosamine and a saccharide, glycopeptide, glycoprotein, protein, peptide, bioconjugate or small molecule by forming an O-glycosidic bond between uridine 5′-diphospho-N-acetylglucosamine and an available hydroxyl group of the saccharide, glycopeptide, glycoprotein, protein, peptide, bioconjugate or small molecule in the presence of an N-acetylglucosaminyltransferase to obtain uridine triphosphate. 16. The method according to claim 13 , wherein the saccharide, glycopeptide, glycoprotein, protein, peptide, bioconjugate or small molecule is a carbohydrate conjugate vaccine or an antibody drug conjugate.

Assignees

Inventors

Classifications

  • C12P19/305Primary

    Pyrimidine nucleotides · CPC title

  • Pentosyltransferases (2.4.2) · CPC title

  • Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases · CPC title

  • Nucleotidyltransferases (2.7.7) · CPC title

  • Acrylic polymers · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11767546B2 cover?
The present invention relates to an enzyme-catalyzed process for producing UDP-N-acetyl-α- D -glucosamine (UDP-GlcNAc) from low-cost substrates uridine monophosphate and N-acetyl- D glucosamine in a single reaction mixture with immobilized or preferably co-immobilized enzymes. Uridine may be used as starting material instead of uridine monophosphate as well. Further, the process may be adapted…
Who is the assignee on this patent?
Max Planck Gesellschaft
What technology area does this patent fall under?
Primary CPC classification C12P19/305. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Sep 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).